Hepatic and glucagon-like peptide-1–mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors
J. Clin. Invest. Kyle W. Sloop, et al. 113:1571 doi:10.1172/JCI20911 [
Go to this article.]
Figure 3GCGR ASO treatment results in α cell hyperplasia. Glucagon immunostaining of representative pancreas sections from 11- to 12-week-old
db+/?,
ob/ob,
db/db mice, and ZDF rats, which had been treated twice per week (every 3.5 days) by subcutaneous injection with control ASO 141923 (upper panels) or GCGR ASO 180475 (lower panels) at 25 mg/kg for 9 total doses. Original magnification,
db+/?, ∞40; others, ∞20).
